Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Cancer
    June 2022
  1. MARTH C, Abreu MH, Andersen KK, Aro KM, et al
    Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
    Cancer. 2022 Jun 17. doi: 10.1002/cncr.34350.
    >> Share

    January 2022
  2. ARUN BK, Peterson SK, Sweeney LE, Bluebond RD, et al
    Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Cancer. 2022;128:94-102.
    >> Share

    December 2021
  3. MCBRIDE CM, Pathak S, Johnson CE, Alberg AJ, et al
    Psychosocial factors associated with genetic testing status among African American women with ovarian cancer: Results from the African American Cancer Epidemiology Study.
    Cancer. 2021 Dec 9. doi: 10.1002/cncr.34053.
    >> Share

  4. MOMTAZ P, O'Connor CA, Chou JF, Capanu M, et al
    Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    Cancer. 2021;127:4393-4402.
    >> Share

    November 2021
  5. TEMKIN SM, Smeltzer MP, Dawkins MD, Boehmer LM, et al
    Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations.
    Cancer. 2021 Nov 17. doi: 10.1002/cncr.34023.
    >> Share

    October 2021
  6. NIERENGARTEN MB
    Rucaparib is a safe and effective maintenance therapy for advanced pancreatic cancer.
    Cancer. 2021;127:3498.
    >> Share

    September 2021
  7. KOTSOPOULOS J, Kim SJ, Armel S, Bordeleau L, et al
    An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    Cancer. 2021;127:3183-3193.
    >> Share

    August 2021
  8. HUEPENBECKER SP, Sun CC, Fu S, Zhao H, et al
    Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States.
    Cancer. 2021 Aug 4. doi: 10.1002/cncr.33829.
    >> Share

    June 2021
  9. MAKHNOON S, Tran G, Levin B, Mattie KD, et al
    Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33668.
    >> Share

    May 2021
  10. KIM SR, Tone A, Kim RH, Cesari M, et al
    Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    Cancer. 2021 May 13. doi: 10.1002/cncr.33625.
    >> Share

    March 2021
  11. LEE CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, et al
    Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Cancer. 2021 Mar 19. doi: 10.1002/cncr.33517.
    >> Share

    February 2021
  12. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Trends and racial disparities in aggressive end-of-life care for a national sample of women with ovarian cancer.
    Cancer. 2021 Feb 25. doi: 10.1002/cncr.33488.
    >> Share

  13. MUKAMA T, Kharazmi E, Sundquist K, Sundquist J, et al
    Risk-adapted starting age of breast cancer screening in women with a family history of ovarian or other cancers: A nationwide cohort study.
    Cancer. 2021 Feb 23. doi: 10.1002/cncr.33456.
    >> Share

  14. SIMON MS, Hastert TA, Barac A, Banack HR, et al
    Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative.
    Cancer. 2021;127:598-608.
    >> Share

    December 2020
  15. PRINTZ C
    Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says.
    Cancer. 2020;126:5007.
    >> Share

    September 2020
  16. GHIRARDI V, Ronsini C, Trozzi R, Di Ilio C, et al
    Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
    Cancer. 2020 Sep 15. doi: 10.1002/cncr.33167.
    >> Share

    August 2020
  17. KIM SR, Tone A, Kim RH, Cesari M, et al
    Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer.
    Cancer. 2020 Aug 18. doi: 10.1002/cncr.33144.
    >> Share

    July 2020
  18. CORR BR, Moroney M, Sheeder J, Eckhardt SG, et al
    Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials.
    Cancer. 2020 Jul 22. doi: 10.1002/cncr.33073.
    >> Share

  19. LUTGENDORF SK, Penedo F, Goodheart MJ, Dahmoush L, et al
    Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.
    Cancer. 2020 Jul 21. doi: 10.1002/cncr.33060.
    >> Share

    June 2020
  20. BLESSING AM, Santiago-O'Farrill JM, Mao W, Pang L, et al
    Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
    Cancer. 2020 Jun 2. doi: 10.1002/cncr.32985.
    >> Share

  21. WESTRICK AC, Bailey ZD, Schlumbrecht M, Hlaing WM, et al
    Residential segregation and overall survival of women with epithelial ovarian cancer.
    Cancer. 2020 Jun 2. doi: 10.1002/cncr.32989.
    >> Share

    May 2020
  22. POORT H, de Rooij BH, Uno H, Weng S, et al
    Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study.
    Cancer. 2020 May 21. doi: 10.1002/cncr.32927.
    >> Share

  23. PRINTZ C
    Research teams unite to develop an early detection test for ovarian cancer.
    Cancer. 2020;126:2113.
    >> Share

    April 2020

  24. The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms.
    Cancer. 2020 Apr 13. doi: 10.1002/cncr.32867.
    >> Share

    March 2020
  25. RUSSO M, Newell JM, Budurlean L, Houser KR, et al
    Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.
    Cancer. 2020 Mar 18. doi: 10.1002/cncr.32822.
    >> Share

    February 2020
  26. PRINTZ C
    Study finds that women with posttraumatic stress disorder have an increased risk of ovarian cancer.
    Cancer. 2020;126:468-469.
    >> Share

  27. VYSOTSKAIA V, Kaseniit KE, Bucheit L, Ready K, et al
    Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Cancer. 2020;126:549-558.
    >> Share

    January 2020
  28. GUO F, Scholl M, Fuchs EL, Berenson AB, et al
    BRCA testing in unaffected young women in the United States, 2006-2017.
    Cancer. 2020;126:337-343.
    >> Share

    December 2019
  29. VERGOTE I, Harter P, Chiva L
    Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer.
    Cancer. 2019;125 Suppl 24:4594-4597.
    >> Share

  30. BOOKMAN MA
    Can we predict who lives long with ovarian cancer?
    Cancer. 2019;125 Suppl 24:4578-4581.
    >> Share

  31. AREND R, Martinez A, Szul T, Birrer MJ, et al
    Biomarkers in ovarian cancer: To be or not to be.
    Cancer. 2019;125 Suppl 24:4563-4572.
    >> Share

  32. LEE JM, Minasian L, Kohn EC
    New strategies in ovarian cancer treatment.
    Cancer. 2019;125 Suppl 24:4623-4629.
    >> Share

  33. SEHOULI J, Grabowski JP
    Surgery in recurrent ovarian cancer.
    Cancer. 2019;125 Suppl 24:4598-4601.
    >> Share

  34. PIGNATA S, Pisano C, Di Napoli M, Cecere SC, et al
    Treatment of recurrent epithelial ovarian cancer.
    Cancer. 2019;125 Suppl 24:4609-4615.
    >> Share

  35. FUJIWARA K, Hasegawa K, Nagao S
    Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy.
    Cancer. 2019;125 Suppl 24:4582-4586.
    >> Share

  36. KOOLE SN, van Driel WJ, Sonke GS
    Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.
    Cancer. 2019;125 Suppl 24:4587-4593.
    >> Share

  37. FRIEDLANDER ML
    Do all patients with recurrent ovarian cancer need systemic therapy?
    Cancer. 2019;125 Suppl 24:4602-4608.
    >> Share

  38. GONZALEZ-MARTIN A, Sanchez-Lorenzo L
    Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
    Cancer. 2019;125 Suppl 24:4616-4622.
    >> Share

  39. HARTER P, Heitz F, Ataseven B, Schneider S, et al
    How to manage lymph nodes in ovarian cancer.
    Cancer. 2019;125 Suppl 24:4573-4577.
    >> Share

    November 2019
  40. CRAFTON SM, Cohn DE, Llamocca EN, Louden E, et al
    Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries.
    Cancer. 2019 Nov 27. doi: 10.1002/cncr.32620.
    >> Share

  41. YANG WL, Lu Z, Guo J, Fellman BM, et al
    Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32582.
    >> Share

  42. SANTIAGO-O'FARRILL JM, Weroha SJ, Hou X, Oberg AL, et al
    Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32600.
    >> Share

    June 2019
  43. HOLLIS RL, Churchman M, Michie CO, Rye T, et al
    High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    Cancer. 2019 Jun 2. doi: 10.1002/cncr.32079.
    >> Share

    May 2019
  44. KAHN RM, Gordhandas S, Maddy BP, Baltich Nelson B, et al
    Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Cancer. 2019 May 31. doi: 10.1002/cncr.32203.
    >> Share

    March 2019
  45. DE ROOIJ BH, Ezendam NPM, Vos MC, Pijnenborg JMA, et al
    Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY Care Trial: New insights for tailored delivery.
    Cancer. 2019;125:788-797.
    >> Share

    December 2018
  46. TEMKIN SM, Mallen A, Bellavance E, Rubinsak L, et al
    The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions.
    Cancer. 2018 Dec 20. doi: 10.1002/cncr.31911.
    >> Share

  47. ESKANDER RN
    Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31902.
    >> Share

  48. BACKES FJ, Haag J, Cosgrove CM, Suarez A, et al
    Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31901.
    >> Share

    November 2018
  49. LAITMAN Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, et al
    Uterine cancer in Jewish Israeli BRCA1/BRCA2 mutation carriers.
    Cancer. 2018 Nov 29. doi: 10.1002/cncr.31842.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016